Skip to content

Comparison of intralesional dexamethasone acetate injection and oral methylprednisolone treatments in women with mass-like Granulomatous Lobular Masti-tis

Comparison of intralesional dexamethasone acetate injection and oral methylprednisolone treatments in women with mass-like Granulomatous Lobular Masti-tis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080599
Enrollment
Unknown
Registered
2024-02-02
Start date
2024-02-02
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulomatous Lobular Mastitis

Interventions

IDACI group/ OM group:None

Sponsors

Department of Thyroid Breast Surgery, Xi’an NO.3 Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (i) Patients in the Department of Thyroid Breast Surgery, Xi’an No.3 Hospital ; (ii) Diagnosis that complies with GLM; (iii) All Patients underwent surgery; (iv) All enrolled patients were diagnosed as mass-like GLM, and the maximum diameter of the mass was =3 cm;

Exclusion criteria

Exclusion criteria: (i) Mass-like GLM patients who were diagnosed during pregnancy or lactation; (ii) Mass-like GLM patients who were with severe cardiac, pulmonary, hepatic and renal insufficiency, such as the presence of cardiovascular, hematopoietic, hepatic and renal diseases; (iii) Mass-like GLM patients who had other diseases affecting the outcome of this study: tumours, allergic diseases, immune diseases, inflammatory diseases in combination with other breast-related diseases or diseases requiring hormonal therapy; (iv) Patients who cannot tolerate surgery or whose hormonal therapy is contraindicated; (v) Mass-like GLM patients who accompanied by breast abscess or sinus tract formation; (vi) Patients who have been treated with immunosuppressive medications or hormones in the past month; (vii) GLM patients who were caused by infection.

Design outcomes

Primary

MeasureTime frame
Clinical efficiency;

Secondary

MeasureTime frame
Time to the remission of symptoms and signs;The incidence of side-effects;The postoperative recurrence rate;

Countries

China

Contacts

Public ContactFUQING JI

Department of Thyroid Breast Surgery, Xi’an NO.3 Hospital

jifuqing1984@126.com+86 180 4943 1984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026